Delivery Order HHSN261201200020I-HHSN26100002
Award Date
9/20/12
Potential Completion Date
9/19/15
Potential Value
$771K
Federal Agency
National Cancer Institute
Awardee
University Of Oklahoma
Ultimate Awardee
University Of Oklahoma
NAICS Category
541711 - Research and Development in Biotechnology
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost No Fee
Place of Performance
Oklahoma City, OK 73104, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award for $686,894.80 by the National Cancer Institute (NCI) under the Preclinical Agent Development Assays 2012-2016 program. The award was made to the University of Oklahoma (OU) to test the efficacy of aspirin and omeprazole for colorectal cancer chemoprevention. This was a delivery order contract with a cost-no-fee pricing type, and there was no set-aside designation. OU is a public research university that provides a range of medical research, healthcare, and...
This federal contract award, valued at $598,079.38, was issued by the National Cancer Institute (NCI) to the University of Oklahoma (OU) Health Sciences Center Division. The contract supports the "COMBINATION OF ASPIRIN OR NAPROXEN WITH OMERPRAZOLE FOR COLORECTAL CANCER CHEMOPREVENTION WITH CLINICALLY RELEVANT DOSES" effort under the NCI's Preclinical Prevent Cancer Program. The contract is a delivery order placed against the NCI's broader "PREVENT Cancer Program (PREVENT)"...
This federal contract award was issued by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to the University of Oklahoma (OU). The $633,898 firm fixed price delivery order is part of NCI's "Preclinical Agent Development Assays 2012-2016" indefinite delivery contract and supports research on the use of the drug naproxen for the prevention of colorectal cancer. The contract does not have a small business set-aside...
This is a $819,519.17 cost-reimbursement delivery order awarded by the National Cancer Institute, a civilian agency of the U.S. Department of Health and Human Services, to the University of Oklahoma Univ Of Oklahoma Health Sciences Center Division. The order is placed under the Preclinical Agent Development Assays 2012-2016 contract vehicle and supports the development of inhibitors for MPGES-1 and 5-LOX proteins for use as colon cancer chemopreventive agents. This work is part of the agency's...
This is a delivery order contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to the University of Oklahoma Univ Of Oklahoma Health Sciences Center Division. The contract is part of the Preclinical Agent Development Assays 2012-2016 indefinite delivery, indefinite quantity (IDIQ) vehicle. It is for "OTHER FUNCTIONS - IN VITRO AND IN VIVO AGENT DEVELOPMENT ASSAYS" services with a ceiling value of $1,899.49....
The federal contract award with ID HHSN261200533000C was issued by the National Cancer Institute, a civilian agency of the U.S. Department of Health and Human Services, to the University of Oklahoma Univ Of Oklahoma Health Sciences Center Division. The contract, valued at $19,658,911.55, is for preclinical efficacy and intermediate endpoint assays. It is a definitive, cost-no-fee contract without a set-aside designation. The University of Oklahoma, as the prime contractor, will provide a range...
This is a firm fixed-price delivery order awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to the University of Oklahoma (OU) for "TARGETING CCK2R FOR PANCREATIC CANCER PREVENTION". The $474,197.46 contract is part of the NCI's Preclinical Agent Development Assays 2012-2016 program, which focuses on preclinical in vitro and in vivo agent development assays. The award does not have a set-aside designation. As...
This is a $521,214.97 Firm Fixed Price delivery order awarded by the National Institutes of Health (NIH) National Cancer Institute to the University of Oklahoma Health Sciences Center to conduct research on the chemoprevention of colorectal cancer with olmesartan medoxomil. The order is part of the NIH's PREVENT Cancer Program, which focuses on preclinical efficacy and intermediate endpoint biomarkers for cancer prevention. The delivery order does not have a set-aside designation. University...
This is a delivery order issued under the National Cancer Institute's PREVENT Cancer Program (PREVENT) contract. The order, valued at $834,263.00, was awarded to the University of Oklahoma Health Sciences Center (OUHSC) to determine the potential clinical usefulness of aspirin and naproxen (another NSAID) for prostate cancer prevention using preclinical models. The University of Colorado-Denver is a subcontractor supporting this research. The award has a period of performance from July 2016 to...
This is a firm fixed-price delivery order contract awarded by the National Cancer Institute, part of the U.S. Department of Health and Human Services, to the University of Oklahoma Univ of Oklahoma Health Sciences Center Division. The $628,343 contract is for research and development related to the Preclinical Prevention Cancer Program, which focuses on preclinical efficacy and intermediate endpoint biomarkers. This work is not set aside for small businesses. The University of Oklahoma, acting...